Please login to the form below

Not currently logged in
Email:
Password:

Zocor

This page shows the latest Zocor news and features for those working in and with pharma, biotech and healthcare.

FDA panel rejects cardiovascular outcomes claim for Vytorin

FDA panel rejects cardiovascular outcomes claim for Vytorin

expire. Vytorin has been a somewhat controversial product for Merck since the publication of the ENHANCE trial, which compared the drug to simvastatin (Merck's now off-patent brand Zocor) alone

Latest news

More from news
Approximately 1 fully matching, plus 43 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics